Ciclopirox: Recent nonclinical and clinical data relevant to its use as a topical antimycotic agent

Drugs

Volumn 70, Issue 16, 2010, Pages 2133-2152

  Subissi, Alessandro ^a   Monti, Daniela ^a   Togni, Giuseppe ^b   Mailland, Federico ^c  

^a UNIVERSITY OF PISA   (Italy)

^b Unilabs   (France)

^c Polichem SA   (Switzerland)

Author keywords

Ciclopirox; Dermatomycoses; Onychomycosis; Seborrhoeic dermatitis; Vulvovaginal candidiasis

Indexed keywords

ANTIFUNGAL AGENT; BIPYRIDINE; CICLOPIROX; CICLOPIROXOLAMINE; CLOTRIMAZOLE; ERGOSTEROL; FENTICONAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LIPOHYDROXY ACID PLUS SALICYLIC ACID; P 3051; PAINT; PLACEBO; SHAMPOO; TERBINAFINE; TOLNAFTATE; UNCLASSIFIED DRUG;

AEROSOL; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; BURNING SENSATION; CANCER PREVENTION; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CREAM; DERMATOMYCOSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ERYTHEMA; FINGER NAIL; GEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOTION; MINIMUM INHIBITORY CONCENTRATION; MUCOSA; MYCOSIS; NONHUMAN; ONYCHOMYCOSIS; REVIEW; SEBORRHEIC DERMATITIS; SEXUALLY TRANSMITTED DISEASE; SKIN IRRITATION; SKIN PAIN; SKIN PENETRATION; SKIN PRURITUS; SKIN REDNESS; TINEA VERSICOLOR; TREATMENT INDICATION; VAGINA CANDIDIASIS; VAGINA FLORA; VAGINA PESSARY;

ARTHRODERMATACEAE; CANDIDA; FUNGI;

EID: 77958612311     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11538110-000000000-00000     Document Type: Review

References (109)

1. Finch JJ, Warshaw EM. Toenail onychomycosis: current and future treatment options. Dermatol Ther 2007; 20: 31-46
2. Topliss D, Gold M, Kotsirilos V, et al. Hepatic reactionswith terbinafine. Australian Adverse Drug Reactions Bull 2008; 27 (1): 3
3. Bennett JE. Antifungal agents. In: Hardman JG, Limbird LE, editors. Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill, 2001: 1295-312
4. Chen SCA, Sorrell TC. Antifungal agents. Med J Aust 2007Oct; 187: 404-9
5. Dubini F, Bellotti MG, Frangi A, et al. In vitro antimycoticactivity and nail permeation models of a piroctone ola-mine (octopirox) containing transungual water soluble technology. Arzneimittelforschung 2005; 55 (8): 478-83
6. Veraldi S, Menter A, Innocenti M. Treatment of mild tomoderate seborrhoeic dermatitis with MAS064D (Seb-clair), a novel topical medical device: results of a pilot, randomized, double-blind, controlled trial. J Eur Acad Dermatol Venereol 2008; 22: 290-6
7. Dittmar W, Lohaus G. HOE 296, a new antimycotic com-pound with a broad antimicrobial spectrum. Arznei-mittelforschung 1973; 23: 670-4
8. Jue SG, Dawson GW, Brogden RN. Cyclopirox olamine1% cream: a preliminary review of its antimicrobial activity and therapeutic use. Drugs 1985; 29: 330-41
9. Kokjohn K, Bradley M, Griffiths B, et al. Evaluation of invitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria. Int J Dermatol 2003; 42 Suppl. 1: 11-7
10. Gupta AK, Kohli Y. In vitro susceptibility testing ofciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br J Dermatol 2003; 149: 296-305
11. Singh J, Zaman M, Gupta AK. Evaluation of microdilu-tion and disk diffusion methods for antifungal susceptibility testing of dermatophytes. Med Mycol 2007; 45 (7): 595-602
12. Shehata AS, Mukherjee PK, Ghannoum MA. Comparisonbetween the standardized clinical and laboratory standards institute M38-A2 method and a 2,3-bis(2-methoxy-4-nitro-5-[(sulphenylamino)carbonyl]-2H-tetrazolium hydroxide-based method for testing antifungal susceptibility of dermatophytes.J Clin Microbiol 2008 Nov; 46(11): 3668-71
13. Czaika V, Tietz HJ, Schmalreck A. Antifungal suscepti-bility testing in chronically recurrent vaginal candidosis as basis for effective therapy. Mycoses 2000; 43 Suppl. 2: 45-50
14. Figueiredo VT, de Assis Santos D, Resende MA, et al.Identification and in vitro antifungal susceptibility testing of 200 clinical isolates of Candida spp. responsible for fingernail infections. Mycopathologia 2007; 164 (1): 27-33
15. Tosti A, Piraccini BM, Lorenzi S. Onychomycosis causedby nondermatophytic molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol 2000 Feb; 42 (2): 217-24
16. Bonifaz A, Cruz-Aguilar P, Ponce RM. Onychomycosis bymolds: report of 78 cases. Eur J Dermatol 2007 Jan-Feb; 17 (1): 70-2
17. Bontems O, Hauser PM, Monod M. Evaluation of a poly-merase chain reaction-restriction fragment length poly-morphism assay for dermatophyte and nondermatophyte identification in onychomycosis. Br J Dermatol 2009 May; 161 (4): 791-6
18. Goudard M, Regli P, Lubrano N. In vitro antifungalspectrum of ciclopiroxolamine. Pathol Biol (Paris) 1989 Jun; 37: 621-3
19. Macura AB, Pawlik B, Szczepko I. The susceptibility ofAspergillus and Penicillium to recent antimycotics. Wiad Parazytol 2000; 46 (1): 157-62
20. Singh J, Rimek D, Kappe R. In vitro susceptibility of 15strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method. Mycoses 2005; 48 (4): 246-50
21. Gemmer CM, DeAngelis YM, Theelen B, et al. Fast, non-invasive method for molecular detection and differentiation of Malassezia yeast species on human skin and application of the method to dandruff microbiology. J Clin Microbiol 2002 Sep; 40 (9): 3350-7
22. Crespo-Erchiga V, Gomez-Moyano E, Crespo M. Pityr-iasis versicolor and the yeasts of genus Malassezia. Actas Dermosifiliogr 2008 Dec; 99 (10): 764-71
23. Roques C, Brousse S, Panizzutti C. In vitro antifungalefficacy of ciclopirox olamine alone and associated with zinc pyrithione compared to ketoconazole against Ma-lassezia globosa and Malassezia restricta reference strains. Mycopathologia 2006; 162 (6): 395-400
24. Gupta AK, Plott T. Ciclopirox: a broad-spectrum antifungalwith antibacterial and anti-inflammatory properties. Int J Dermatol 2004; 43 Suppl. 1: 3-8
25. Carrillo-Munoz AJ, Giuliano G, Ezkurra PA, et al. Anti-fungal agents: mode of action in yeast cells. Rev Esp Quimioterap 2006; 19: 130-9
26. Abrams BB, Hanel H, Hoehler T. Ciclopirox olamine: ahydroxypyridone antifungal agent. Clin Dermatol 1991; 9: 471-7
27. Niewerth M, Kunze D, Seibold M, et al. Ciclopirox ola-mine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob Agents Chemother 2003; 47: 1805-17
28. Sigle HC, Thewes S, Niewerth M, et al. Oxygen accessi-bility and iron levels are critical factors for the antifungal action of ciclopirox against Candida albicans. J Anti-microb Chemother 2005; 55: 663-73
29. Sigle HC, Schafer-Korting M, Korting HC, et al. In vitroinvestigations on the mode of action of the hydroxy-pyridone antimycotics rilopirox and piroctone on Candida albicans. Mycoses 2006; 49 (3): 159-68
30. Lee RE, Liu TT, Barker KS. Genome-wide expressionprofiling of the response to ciclopirox olamine in Candida albicans. J Antimicrob Chemother 2005; 55: 655-62
31. Braga PC, Piatti G, Conti E, et al. Effects of subinhibitoryconcentrations of ciclopirox on the adherence of Candida albicans to human buccal and vaginal epithelial cells. Arzneimittelforschung 1992; 42: 1368-71
32. De Bernardis F, Sullivan PA, Cassone A. Aspartyl protein-ases of Candida albicans and their role in pathogenicity. Med Mycol 2001; 39: 303-13
33. Schaller M, Krnjaic N, Niewerth M, et al. Effect of anti-mycotic agents on the activity of aspartyl proteinasessecreted by Candida albicans. J Med Microbiol 2003; 52: 247-9
34. Sakurai K, Sagakuchi T, Yamaguchi H, et al. Mode of actionof 6-cyclohexyl-l-hydroxy-4-methyl-2(1H) pyridone ethanol-amine salt (Hoe 296). Chemotherapy 1978; 24: 68-76
35. Carrillo-Munoz AJ, Brio S, Alonso R, et al. Ciclopirox-olamine: in vitro antifungal activity against clinical yeast isolates. Int J Antimicrob Agents 2002; 20 (5): 375-9
36. Tietz HJ. Therapy problems in chronic recurrent vaginalmycosis. Ther Umsch 2002; 59 (9): 481-4
37. Hanel H, Smith-Kurtz E, Pastowsky S. Therapy of sebor-rheic eczema with an antifungal agent with an antiphlogistic effect. Mycoses 1991; 34 Suppl. 1: 91-3
38. Rosen T, Schell B, Orengo I. Anti-inflammatory activity ofantifungal preparations. Int J Derm 1997; 36: 788-92
39. Lassus A, Nolting KS, Savopoulos C. Comparison of ciclo-pirox 1% hydrocortisone acetate 1% cream in the treatment of inflamed superficial mycoses. Clin Ther 1988; 10: 594-9
40. Nakashima T, Sato E, Niwano Y, et al. Inhibitory orscavenging action of ketoconazole and ciclopiroxolamine against reactive oxygen species released by primed inflammatory cells. Br J Dermatol 2007; 156 (4): 720-7
41. Sato E, Kohno M, Nakashima T, et al. Ciclopirox olaminedirectly scavenges hydroxyl radical. Int J Dermatol 2008; 47 (1): 15-8
42. Zaneveld LJ, Waller DP, Sellors J, et al. Ciclopirox-olamine: a vaginal product with microbicide potential [online]. Available from URL: www.path.org/files/TS- ciclo-microb-poster.pdf [Accessed 2009 Jul 25]
43. Hoque M, Hanauske-Abel HM, Palumbo P, et al. Inhibi-tion of HIV-1 gene expression by ciclopirox and defer-iprone, drugs that prevent hypusination of eukaryotic initiation factor 5A. Retrovirology 2009 Oct 13; 6: 90
44. Clement PM, Hanauske-Abel HM, Wolff EC. The anti-fungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro. Int J Cancer 2002; 100 (4): 491-8
45. Park JH, Aravind L, Wolff EC, et al. Molecular cloning,expression, and structural prediction of deoxyhypusine hydroxylase: a HEAT-repeat-containing metalloenzyme. Proc Natl Acad Sci \USA 2006; 103 (1): 51-6
46. Cracchiolo B. Chemoprevention of cancer in the lower femalegenital tract: the antineoplastic activity of the fungicide ciclopirox [ClinicalTrials.gov identifier NCT00382330]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2009 Jul 25]
47. Eberhard Y, McDermott SP, Wang X, et al. Chelation ofintracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 2009; 114 (14): 3064-73
48. Zhou H, Shen T, Luo Y, et al. The antitumor activity of thefungicide ciclopirox. Int J Cancer. Epub 2010 Mar 11S
49. Saeftel M, Sarite RS, Njuguna T, et al. Piperidones withactivity against Plasmodium falciparum. Parasitol Res 2006; 99 (3): 281-6
50. Kellner HM, Amold C, Christ OE. Untersuchungenzur Pharmakokinetik und Biotrasformation des Anti-mykotikums Cicclopiroxolamin bei Tieren und beiMenschen nach topischer und systemischer Anwendung. Arzneimittelforschung 1981; 31: 1337-53
51. Bonelli M, Cattabeni F, Ragusa MC, et al. Escrezione ur-inaria della ciclopirox olamina dopo applicazione topica sulla cute umana. Ann It Derm Clin Sper 1983; 37: 397-401
52. Ceschin-Roques CG, Hanel H, Pruja-Bougaret SM, et al.Ciclopiroxolamine cream 1%: in vitro and in vivo penetration into the stratum corneum. Skin Pharmacol 1991; 4 (2): 95-9
53. Coppi G, Silingardi S, Girardello R. Pharmacokinetics ofciclopirox olamine after vaginal application to rabbits and patients. J Chemother 1993; 5: 302-6
54. Messina P, Girardello R, Giannella C, et al. Systemicbioavailability study of ciclopirox olamine vaginal ovules (Dafnegin®) administered in repeated dose regimen to 6 females suffering from vaginal infections due to Candida. Lugano: Polichem SA, 1997. (Data on file)
55. Bohn M, Kraemer KT. Dermatopharmacology of ciclo-pirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000 Oct; 43 (4): S57-69
56. Monti D, Saccomani L, Chetoni P, et al. In vitro transun-gual permeation of ciclopirox from a hydroxypropyl chitosan-based, water-soluble nail lacquer. Drug Dev Ind Pharm 2005 Jan; 31 (1): 11-7
57. Monti D, Saccomani L, Chetoni P, et al. Hydrosolublemedicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity. Br J Dermatol 2009; 162: 311-7
58. Monti D, Saccomani L, Chetoni P, et al. Development of adrug permeation model through human infected nails and relationship with bovine hoof slices. J Invest Dermatol 2007; 127 Suppl. 2: S64
59. Mailland F, Baran R, Caserini M. Pharmacokinetic/pharmacodynamic relationship of a new nail lacquer in the treatment of onychomycosis [poster]. 6th European Academy of Dermatology and Venereology (EADV) Spring Symposium: Skin and quality of life; 2009 Apr 23-26
60. BucharestGupta AK, Skinner AR. Ciclopirox for the treatment ofsuperficial fungal infections: a review. Int J Dermatol 2003; 42 Suppl. 1: 3-9
61. del Palacio A, Cuetara MS, Lopez-Suso MJ, et al. Ran-domized prospective comparative study: short-term treatment with ciclopiroxolamine (cream and solution) versus boric acid in the treatment of otomycosis. Mycoses 2002 Oct; 45 (8): 317-28
62. Szeimies RM, Wimmershoff MB, Reisberger EM, et al.Treatment of therapy refractory verrucae vulgares with a ciclopirox-containing lacquer [in German]. Hautarzt 2001 Jun; 52 (6): 489-91
63. Adam W, Peil HG, Savopoulos C, et al. Clinical resultswith the antimycotic agent ciclopiroxolamine [in German]. Arzneimittelforschung 1981; 31 (8A): 1360-5
64. Torres J, Savopoulos C, Dittmar W. Open clinical trial indermal mycoses of a 1% ciclopiroxolamine solution in polyethylene glycol 400 carried out in FR Germany/study with shortened therapy [in German]. Arzneimittelforschung 1981; 3: 1373-6
65. Fredriksson T, Savopoulos C. Comparative double-blindstudy on ciclopiroxolamine cream and placebo cream in dermatophytosis [in German]. Arzneimittelforschung 1981; 31 (8A): 1376-8
66. Beyer M. Selected double-blind comparative studies on theefficacy and tolerance of ciclopiroxolamine solution and cream [in German]. Arzneimittelforschung 1981; 31 (8A): 1378-81
67. Dittmar W. Non-European open clinical studies on theefficacy and tolerance of ciclopiroxolamine in dermato-mycoses [in German]. Arzneimittelforschung 1981; 31 (8A): 1381-5
68. Bagatell FK, Bogaert H, Cullen SI, et al. Evaluation ofa new antifungal cream, ciclopirox olamine 1% in the treatment of cutaneous candidosis. Clin Ther 1985; 8: 41-8
69. Kligman AM, Bogaert H, Cordero C, et al. Evaluation ofciclopirox olamine cream for the treatment of tinea pedis: multicenter, double-blind, comparative studies. Clin Ther 1985; 7: 409-17
70. Cullen SI, Jacobson C, Kanof NB, et al. Treatment of tineaversicolor with a new antifungal agent, ciclopirox olamine cream 1%. Clin Ther 1985; 7: 574-83
71. Bogaert H, Cordero C, Ollague W, et al. Multicentredouble-blind clinical trials of ciclopirox olamine cream 1% in the treatment of tinea corporis and tinea cruris. J Int Med Res 1986; 14: 210-6
72. Corte M, Jung K, Linker U, et al. Topical application ofa 0.1% ciclopiroxolamine solution for the treatment of pityriasis versicolor. Mycoses 1989; 32 (4): 200-3
73. Aly R, Maibach HI, Bagatell FK, et al. Ciclopirox olaminelotion 1%: bioequivalence to ciclopirox olamine cream 1% and clinical efficacy in tinea pedis. Clin Ther 1989; 11: 290-303
74. Altmeyer P, Nolting S, Kuhlwein A, et al. Effect of fenti-conazole spray in cutaneous mycosis: a double-blind clinical trial versus cyclopyrox olamine spray. J Int Med Res 1990; 18 (1): 61-7
75. Wu YC, Chuan MT, Lu YC. Efficacy of ciclopiroxolamine1% cream in onychomycosis and tinea pedis. Mycoses 1991; 4: 93-5
76. Aly R, Fisher G, Katz I, et al. Ciclopirox gel in the treat-ment of patients with interdigital tinea pedis. Int J Der-matol 2003 Sep; 42 Suppl. 1: 29-35
77. Gupta AK, Skinner AR, Cooper EA. Evaluation of theefficacy of ciclopirox 0.77% gel in the treatment of tinea pedis interdigitalis (dermatophytosis complex) in a randomized, double-blind, placebo-controlled trial. Int J Dermatol 2005; 44 (7): 590-3
78. Wajnberg M, Wajnberg A. Doppelblind-Vergleichsstudiemit Ciclopiroxolamin-und Miconazol-Vaginal creme bei vulvovaginaler Candidose [A comparative double blind trial with vaginal creams of cyclopyroxolamine and mi-conazole in vulvovaginal candidosis (author's transl); in German]. Mykosen 1981; 24 (12): 721-30
79. Garca Figueroa RG, Sauceda L, Ramrez PalaciosD, et al.Effectiveness and safety of ciclopirox olamine 1% vaginal cream versus terconazole 0.8% vaginal cream in the treatment of genital candidiasis. Ginecol Obstet Mex 2000; 68: 154-9.
80. Queiroz JL, Cymbalista NB. Estudio clinico com ciclopiroxcreme vaginal na candidiase vulvovaginal. Rev Bras Clin Ter 1980; 37: 479-84
81. Peil HG. Offene Studio zur Wirksamkeit und Vertrflglich-keit von Ciclopiroxolamin bei vulvovaginaler Candidose [Open clinical study on the efficacy and tolerance of ciclopiroxolamine in vulvovaginal candidosis (author's transl); in German]. Arzneimittelforschung 1981; 31 (8A): 1366-8
82. Damianov L, Novachkov V, Ivanov S. The treatment ofacute mycotic colpitis with ciclopiroxolamine in patients using oral contraceptives [in Bulgarian]. Akush Ginekol (Sofiia) 1997; 36 (1): 32-3
83. Novachkov V, Damianov L, Tsankova M, et al. Thetreatment of acute mycotic colpitis with ciclopirox ola-mine in pregnant patients in the 10th lunar month [in Bulgarian]. Akush Ginekol (Sofiia) 1999; 38 (4): 54-5
84. Giannoni M, Pollastro M, Jacobellis M. A clinical study ofcyclopyroxolamine versus clotrimazole in the treatment of mycotic vulvovaginitis [in Italian]. Minerva Med 1990; 81: 555-9
85. Nencioni T, Pamparana F, Jacobellis M. Mycotic vulvo-vaginitis and topical cyclopiroxolamine [in Italian]. Minerva Ginecol 1988; 40: 719-22
86. Bucciero A, Molteni E, Molteni B, et al. Ciclopiroxolaminein the topical treatment of vaginal mycoses [in Italian]. Minerva Ginecol 1989; 41: 283-6
87. Shuttleworth D, Squire RA, Boorman GC, et al. Com-parative clinical efficacy of shampoos containing ciclo-pirox olamine (1.5%) or ketonazole (2%) for the control of dandruff/seborrheic dermatitis. J Dermatol Treat 1998; 9: 157-62
88. Vardy DA, Zvulunov A, Tchetov T, et al. A double-blind,placebo-controlled trial of a ciclopirox olamine 1% shampoo for the treatment of scalp seborrheic dermatitis. J Dermatol Treat 2000; 11: 73-7
89. Dupuy P, Maurette C, Amoric JC, et al., on behalf of theStudy Investigator Group. Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclo-piroxolamine 1% cream in facial seborrhoeic dermatitis. Br J Dermatol 2001; 144 (5): 1033-7
90. Squire RA, Goode K. A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. J Der-matolog Treat 2002; 13 (2): 51-60
91. Unholzer A, Varigos G, Nicholls D, et al. Ciclopirox-olamine cream for treating seborrheic dermatitis: a double-blind parallel group comparison. Infection 2002; 30 (6): 373-6
92. Aly R, Katz HI, Kempers SE, et al. Ciclopirox gel forseborrheic dermatitis of the scalp. Int J Dermatol 2003; 42 Suppl. 1: 19-22
93. Lebwohl M, Plott T. Safety and efficacy of ciclopirox 1%shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial. Int J Dermatol 2004; 43 Suppl. 1: 17-20
94. Altmeyer P, Hoffmann K, on behalf of the Loprox ShampooDosing Concentration Study Group. Efficacy of different concentrations of ciclopirox shampoo for the treatment of seborrheic dermatitis of the scalp: results of a randomized,double-blind, vehicle-controlled trial. Int J Dermatol 2004; 43 Suppl. 1: 9-12
95. Abeck D, on behalf of the Loprox Shampoo Dosing StudyGroup. Rationale of frequency of use of ciclopirox 1% shampoo in the treatment of seborrheic dermatitis: results of a double-blind, placebo-controlled study comparing the efficacy of once, twice, and three times weekly usage. Int J Dermatol 2004; 43 Suppl. 1: 13-6
96. Shuster S, Meynadier J, Kerl H, et al. Treatment and pro-phylaxis of seborrheic dermatitis of the scalp with anti-pityrosporal 1% ciclopirox shampoo. Arch Dermatol 2005; 141 (1): 47-52
97. Mayser P, Kupfer J, Nemetz D, et al. Treatment of headand neck dermatitis with ciclopiroxolamine cream: results of a double-blind, placebo-controlled study. Skin Pharmacol Physiol 2006; 19: 153-8
98. Ratnavel RC, Squire RA, Boorman GC. Clinical efficaciesof shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis. J Dermatolog Treat 2007; 18 (2): 88-96
99. Seite S, Rougier A, Malarico S. Randomized study com-paring the efficacy and tolerance of a lipohydroxy acid shampoo to a ciclopiroxolamine shampoo in the treatment of scalp seborrheic dermatitis. J Cosmet Dermatol 2009; 8: 249-53
100. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquertopical solution 8% in the treatment of toenail onycho-mycosis. J Am Acad Dermatol 2000; 43 (4 Suppl.): S70-80
101. Seebacher C, Nietsch KH, Ulbricht HM. A multicenter,open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomy-cosis in patients with diabetes [published erratum appears in Cutis 2001; 68 (4): 296]. Cutis 2001; 68 (2 Suppl.): 17-22
102. Brenner MA, Harkless LB, Mendicino RW, et al. Ciclo-pirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study. J Am Podiatr Med Assoc 2007; 97 (3): 195-202
103. Baran R, Tosti A, Hartmane I, et al. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol 2009; 23 (7): 773-81
104. Gupta AK, Bluhm R. Ciclopirox (Loprox) gel for superficialfungal infections. Skin Therapy Lett 2004 Aug-Sep; 9: 4-5
105. Gupta AK, Nicol KA. Ciclopirox 1% shampoo for thetreatment of seborrheic dermatitis. Int J Dermatol 2006 Jan; 45 (1): 66-9
106. Ciclopirox olamine: clinical overview. Lugano, Switzerland :Polichem SA, 2008. (Data on file)
107. Gupta AK, Ryder JE, Baran R. The use of topical therapiesto treat onychomycosis. Dermatol Clin 2003; 21: 481-9
108. Gupta AK, Schouten JR, Lynch LE. Ciclopirox nail lac-quer 8% for the treatment of onychomycosis: a Canadian perspective. Skin Therapy Lett 2005 Sep; 10 (7): 1-3
109. Sweetman SC, editor. Martindale: the complete drug re-ference. 35th ed. London: Pharmaceutical Press, 2007: 477